Teriparatide is a lab-made form of a portion of human parathyroid hormone that helps build new bone. It belongs to a class of medicines called bone-forming (anabolic) agents, used to treat osteoporosis in people at high risk of fracture. It is a prescription-only, self-injectable medicine.

• Therapeutic Class: Bone-forming (anabolic) osteoporosis therapy.

• Pharmacological Class: Parathyroid hormone (PTH) analog.

• Drug Family: Recombinant human PTH (1-34) fragment therapies.

• ATC Classification: H05AA02 (Teriparatide).

Approved: Osteoporosis in postmenopausal women and men at high risk of fracture, and glucocorticoid-induced osteoporosis in men and women at high risk of fracture.

Commonly used for: Patients with severe osteoporosis or those who have already had a fragility fracture, particularly when bone-building rather than just bone-preserving treatment is needed.

Off-label use (only under medical guidance): Occasionally used to support fracture healing in specific clinical situations, under specialist judgement.

● Injection (multi-dose prefilled pen): 20 mcg/dose (250 mcg/mL), delivering 28 daily doses per pen.

Unlike continuous high levels of parathyroid hormone (which break down bone), teriparatide is given as a short daily pulse, which instead stimulates osteoblasts, the cells that build new bone. This leads to increased bone formation and improved bone strength over time.

• Standard dose: 20 mcg injected subcutaneously once daily, in the thigh or abdominal wall.

• Condition-wise dose: Treatment duration is individualised; earlier prescribing guidance limited lifetime use to 2 years, though this restriction has since been removed from the U.S. label based on longer-term real-world safety data.

• Route: Subcutaneous injection, self-administered at home after training.

• Missed dose: Take as soon as remembered that day; don't double up — resume the regular daily schedule.

• Overdose: May cause nausea, dizziness, low blood pressure, or significant changes in blood calcium; requires medical attention.

• Common: Nausea, joint pain, leg cramps, and dizziness.

• Serious: Transient rise in blood calcium after each dose, and (historically flagged, based on rat studies) a possible bone cancer (osteosarcoma) risk — a concern not confirmed in large human studies and no longer carrying a boxed warning on the current U.S. label.

• Emergency symptoms: Severe dizziness or fainting shortly after injection, signs of a serious allergic reaction, or new unexplained bone pain.

• Recovery advice: Mild dizziness or lightheadedness can occur shortly after the first few doses; taking the injection while seated and moving slowly afterward can help until this is known to settle.

• Pregnancy: Not indicated, as osteoporosis treatment doesn't apply to this population.

• Breastfeeding: Used with caution and medical guidance given a theoretical tumorigenicity signal from animal studies.

• Liver disease: No specific dose adjustment established; used with routine monitoring.

• Kidney disease: Used with caution; blood calcium is monitored more closely.

• Elderly: Commonly used in this age group, as osteoporosis is more prevalent with age.

• Children: Not approved; should not be used in patients with open growth plates or increased baseline osteosarcoma risk.

● Digoxin: teriparatide's transient effect on blood calcium may theoretically increase digoxin's effects; caution advised.

● Other bone-active medicines (bisphosphonates): concurrent use may blunt teriparatide's bone-building effect; sequencing is usually planned rather than combined simultaneously.

● Medicines affecting calcium levels: combined use requires closer monitoring of blood calcium.

● Serum calcium levels periodically.

● Bone density scans to track treatment response.

● Assessment for symptoms of hypercalcemia, especially early in treatment.

● Review of baseline osteosarcoma risk factors before starting.

Romosozumab (another bone-forming agent); Denosumab, Alendronate, Zoledronic acid (anti-resorptive agents, often used after a course of teriparatide).

Typically used as a standalone bone-building course, often followed by an anti-resorptive medicine (such as a bisphosphonate or denosumab) to help maintain the bone gains achieved.

● Osteoporosis Medicines

● Bone-Forming (Anabolic) Therapies

● Parathyroid Hormone Analogs

1. 6 Super Foods For Osteoporosis

2. Genuine Osteoporosis Medicines Online in India

1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021318s053lbl.pdf

2. https://academic.oup.com/jbmrplus/article/6/9/e10665/7479075

The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.